Amino Acid Metabolism and Urea Cycle

Amino Acid Catabolism

• Amino acids are deaminated through transaminases and oxidative deaminases, transferring the amino group to α-ketoglutarate (forming glutamate) or directly releasing free ammonia
• The carbon skeleton is converted to pyruvate, acetyl-CoA, or TCA cycle intermediates and used for gluconeogenesis, lipogenesis, or energy production
• Branched-chain amino acids (leucine, isoleucine, valine) are metabolized primarily in muscle and are essential amino acids that cannot be synthesized de novo

The Urea Cycle - Six Critical Enzymes

• Carbamoyl phosphate synthetase I (CPS I) catalyzes the first committed step: ammonia + CO₂ + 2 ATP → carbamoyl phosphate (requires N-acetylglutamate as allosteric activator)
• Ornithine transcarbamylase (OTC) condenses carbamoyl phosphate with ornithine to form citrulline; the most commonly deficient enzyme in urea cycle defects
• Argininosuccinate synthetase adds aspartate to citrulline forming argininosuccinate; fumarate links the urea cycle to the TCA cycle
• Argininosuccinate lyase cleaves argininosuccinate into arginine and fumarate
• Arginase hydrolyzes arginine to urea (excreted) and ornithine (recycled); ornithine is regenerated to continue the cycle
• N-acetylglutamate synthase produces the essential allosteric activator; deficiency causes secondary urea cycle dysfunction

Ammonia Toxicity Mechanisms

• Ammonia crosses the blood-brain barrier via the glutamine transporter and disrupts cerebral energy metabolism by depleting α-ketoglutarate needed for the TCA cycle
• Hyperammonemia shifts glutamate metabolism toward glutamine synthesis, depleting the critical neurotransmitter glutamate and impairing GABA synthesis
• Elevated glutamine causes osmotic stress, cerebral edema, and impaired synaptic function
• Oxidative stress and mitochondrial dysfunction further damage neurons, particularly in astrocytes

Neonatal Presentation (Days 2-7 of life)

• Poor feeding, vomiting, lethargy, and hypotonia progressing to seizures and coma within 24-72 hours of symptom onset
• Respiratory alkalosis (from direct ammonia stimulation of respiratory centers) followed by metabolic acidosis
• Hypothermia, irritability, and characteristic "musty" or "sweaty feet" odor (in some conditions)
• Classic pearl: Presentation often follows protein feeding (breast milk or formula) as protein catabolism increases ammonia production

Late-Onset Presentation (Weeks to months)

• Failure to thrive, developmental delay, and behavioral changes
• Periodic episodes of vomiting, lethargy, and encephalopathy triggered by illness, high protein intake, or stress
• Ataxia, tremor, and progressive neurological deterioration between episodes
• May be mistaken for primary neurologic or psychiatric disease

Laboratory Abnormalities

• Elevated plasma ammonia (normal: <50 μmol/L; diagnostic if >200 μmol/L in symptomatic patients)
• Hyperglutaminemia and glutamine/glutamate ratio >0.7 (most sensitive marker of hyperammonemia)
• Low plasma arginine and citrulline (depending on which enzyme is deficient)
• Elevated urinary orotic acid (particularly in OTC deficiency due to carbamoyl phosphate shunting to pyrimidine synthesis)
• Elevated plasma alanine reflecting increased amino acid catabolism

Important Clinical Pearls

• Symptom severity correlates with ammonia level only imperfectly; acute rise in ammonia is more neurotoxic than chronically elevated levels
• Female carriers of X-linked OTC deficiency may present with encephalopathy if skewed X-inactivation favors the mutant allele

Step 1: Clinical Suspicion

• Hyperammonemia (>150 μmol/L) with encephalopathy, especially in neonates or with family history of unexplained encephalopathy or sudden infant death
• Unexplained seizures, developmental delay, or ataxia in children
• Elevated ammonia out of proportion to liver function tests or liver size

Plasma and Urine Amino Acid Analysis

• Plasma amino acids distinguish specific urea cycle defects: low arginine/citrulline with high glutamine in CPS I or OTC deficiency; high citrulline in argininosuccinate synthetase deficiency
• Urine orotic acid is markedly elevated in OTC deficiency (>1000-fold normal) due to carbamoyl phosphate being shunted to pyrimidine synthesis
• Urine amino acids show lysinuria in some conditions

Enzyme Activity Assays

• Direct measurement of specific urea cycle enzyme activity in liver biopsy samples (definitive diagnosis)
• Fibroblast assays can identify CPS I, argininosuccinate synthetase, and arginase deficiencies
• OTC activity measured in liver tissue or by genetic testing (particularly important in females)

Genetic Testing

• DNA sequencing of urea cycle genes (OTC, CPS1, ASS1, ASL, ARG1, NAGS) now first-line in many centers
• Identifies pathogenic variants and enables carrier screening in family members
• Essential for genetic counseling and prenatal diagnosis

Important Diagnostic Considerations

• Obtain ammonia level URGENTLY and during acute symptoms when possible; ammonia rapidly decreases after treatment, making retrospective diagnosis difficult
• Normal ammonia does not exclude the diagnosis if sampled after recovery; repeat sampling during episodes may be needed
• Differentiate primary urea cycle defects from secondary hyperammonemia (liver disease, certain drugs, organic acidemias, fatty acid oxidation defects, infection)

Acute Hyperammonemia Management (Medical Emergency)

• Discontinue protein intake immediately and start high-dose IV dextrose/lipid (200-250 g/day glucose) to suppress catabolism and provide non-protein calories
• Nitrogen scavenging agents: Sodium phenylbutyrate (250-350 mg/kg/day IV divided in 4 doses) conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, removing nitrogen without forming ammonia; OR sodium benzoate (250-350 mg/kg/day) which conjugates with glycine
• Sodium phenylacetate combined with arginine (2-6 g/kg/day IV divided doses) enhances nitrogen removal and restores arginine levels; arginine is essential in all urea cycle defects except arginase deficiency
• Monitor ammonia levels every 4-6 hours during acute crisis; goal is <150 μmol/L; aggressive correction needed if >250 μmol/L with neurologic symptoms
• Hemodialysis or hemofiltration for ammonia >400-500 μmol/L unresponsive to medical therapy or with worsening encephalopathy; removes both ammonia and nitrogen-containing compounds more efficiently than peritoneal dialysis

Chronic Maintenance Therapy

• Protein restriction (0.5-1.5 g/kg/day depending on age and enzyme defect) with supplementation of essential amino acids and arginine; goal is adequate nutrition without excessive nitrogen load
• Continuous sodium phenylbutyrate or glycerol phenylbutyrate (3-5 g/day divided BID-QID) as maintenance to chronically reduce ammonia

• Ammonia first, always: in any encephalopathic neonate or unexplained lethargy/vomiting after protein feeds, the single best next step is a stat plasma ammonia drawn free-flowing and placed on ice — the sample degrades and normalizes quickly after treatment. Do not wait for the metabolic panel to return.
• Respiratory alkalosis is the discriminator: ammonia directly stimulates the brainstem respiratory center, so early urea cycle defects give a tachypneic, alkalotic neonate. An anion-gap metabolic acidosis with ketosis instead points to an organic acidemia (methylmalonic, propionic) as the cause of secondary hyperammonemia.
• Urinary orotic acid splits the top two: markedly elevated orotic acid = OTC deficiency (X-linked, carbamoyl phosphate spills into pyrimidine synthesis); low/absent orotic acid with the same picture = CPS I deficiency (autosomal recessive). Do not confuse OTC with hereditary orotic aciduria, which causes megaloblastic anemia unresponsive to B12/folate and has a normal ammonia.
• Arginine is the exception trap: arginine becomes conditionally essential in every urea cycle defect except arginase deficiency, where supplementing it worsens disease. Also recall valproate as a classic acquired precipitant of hyperammonemia.
• PKU buzzwords: musty/mousy odor, fair skin and hair, eczema, intellectual disability. Phenylalanine hydroxylase (or BH₄ cofactor) deficiency makes tyrosine conditionally essential. ACMG guidance supports lifelong blood phenylalanine control within the therapeutic range, dietary Phe restriction with tyrosine supplementation, avoidance of aspartame, and sapropterin in BH₄-responsive patients. Maternal PKU — strict preconception control prevents fetal microcephaly, congenital heart disease, and growth restriction; ACOG echoes this.
• Homocystinuria vs Marfan: cystathionine β-synthase deficiency gives marfanoid habitus plus downward and inward lens subluxation, thrombosis, and intellectual disability; Marfan lenses dislocate upward. Roughly half are pyridoxine (B6)-responsive; adjuncts include betaine, folate, and B12.
• Cofactor associations examiners love: transaminases (ALT/AST) require pyridoxal phosphate, which is why isoniazid depletes B6; branched-chain ketoacid dehydrogenase in maple syrup urine disease requires thiamine and gives a burnt-sugar odor.
• Screening pearl: PKU, MSUD, homocystinuria, citrullinemia, and argininosuccinic aciduria are on the federal Recommended Uniform Screening Panel; OTC deficiency is not reliably detected by newborn screening, so clinical vigilance remains the safeguard.